Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Hashimoto H, et al. Among authors: tokuyama o. Lancet Oncol. 2020 Feb;21(2):242-249. doi: 10.1016/S1470-2045(19)30678-3. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838011 Clinical Trial.
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R, Matsumura N, Michimae H, Tanabe H, Yunokawa M, Iwase H, Sasagawa M, Nakamura T, Tokuyama O, Takano M, Sugiyama T, Sawasaki T, Isonishi S, Takehara K, Nakai H, Okamoto A, Mandai M, Konishi I. Murakami R, et al. Among authors: tokuyama o. Gynecol Oncol. 2019 May;153(2):312-319. doi: 10.1016/j.ygyno.2019.02.010. Epub 2019 Mar 8. Gynecol Oncol. 2019. PMID: 30853361 Clinical Trial.
The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Kondo E, Tabata T, Suzuki N, Aoki D, Yahata H, Kotera Y, Tokuyama O, Fujiwara K, Kimura E, Terauchi F, Sumi T, Okamoto A, Yaegashi N, Enomoto T, Sugiyama T. Kondo E, et al. Among authors: tokuyama o. J Gynecol Oncol. 2020 Nov;31(6):e94. doi: 10.3802/jgo.2020.31.e94. J Gynecol Oncol. 2020. PMID: 33078599 Free PMC article. Clinical Trial.
Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).
Yano M, Nasu K, Yasuda M, Katoh T, Kagabu M, Kobara H, Matsuura M, Tokuyama O, Yamawaki T, Wakahashi S, Noguchi T, Mizuno K, Shitsukawa K, Onohara Y, Nakabori T, Miyasaka A, Nakao T, Matsunaga T, Kunimi Y, Sakurai M, Uchiyama A, Itoh R, Ohike N, Hirakawa T, Watanabe T, Nishino K, Motohashi T, Ito K. Yano M, et al. Among authors: tokuyama o. Melanoma Res. 2022 Jun 1;32(3):150-158. doi: 10.1097/CMR.0000000000000811. Epub 2022 Mar 29. Melanoma Res. 2022. PMID: 35377861
19 results